KPI 10

Drug Profile

KPI 10

Alternative Names: KPI-10; WQ-3810; WQ-3813

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Wakunaga Pharmaceutical
  • Developer Kalidex Pharmaceuticals
  • Class Antibacterials; Fluoroquinolones
  • Mechanism of Action DNA gyrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Bacterial infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Bacterial-infections(In volunteers) in USA (PO)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Bacterial-infections in USA (IV)
  • 12 Sep 2012 Pharmacokinetic, antimicrobial, and adverse events data from preclinical trials in Bacterial infections presented at the 52nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2012) ,,,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top